---
title: HIV, Equity, and Addiction Training (HEAT) Program
nct_id: NCT06370481
overall_status: RECRUITING
phase: NA
sponsor: University of Alabama at Birmingham
study_type: INTERVENTIONAL
primary_condition: Substance Use Disorders
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06370481.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06370481"
ct_last_update_post_date: 2026-02-18
last_seen_at: "2026-05-12T06:29:51.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# HIV, Equity, and Addiction Training (HEAT) Program

**NCT ID:** [NCT06370481](https://clinicaltrials.gov/study/NCT06370481)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** University of Alabama at Birmingham
- **Collaborators:** National Institute on Drug Abuse (NIDA)
- **Conditions:** Substance Use Disorders, Hiv, Opioid Use Disorder, Stimulant Use (Diagnosis)
- **Start Date:** 2026-01-29
- **Completion Date:** 2029-06
- **CT.gov Last Update:** 2026-02-18

## Brief Summary

This project is a pilot study to determine the feasibility and acceptability of a telemedicine intervention for substance use disorder service delivery in diverse people living with HIV in Alabama.

## Detailed Description

The contemporary drug crisis and the COVID-19 pandemic have exposed the complex syndemics of addiction and infectious diseases: rising rates of substance use disorder (SUD) have outpaced our ability to respond with a limited healthcare workforce and public health capacity. SUD is increasing in those living with and at risk for HIV, and infectious consequences of SUD, like hepatitis C, have continued, unmitigated, in rural parts of the U.S. where many states lack Medicaid expansion, syringe service programs, and public health infrastructure to respond to the drug crisis and comorbid infections. Systemic racism and regressive policies in the Deep South criminalize people who use drugs, creating additional barriers to care, HIV prevention, and addiction treatment. As a result, people who use drugs rarely receive comprehensive addiction and HIV treatment. Yet telemedicine has the potential to overcome these barriers and bypass the constraints of a brick-and-mortar clinic to link vulnerable people, including those with HIV, to care. Although telemedicine has become mainstream in recent years, few studies have evaluated telemedicine for SUD in the Deep South from the perspective of patients and providers.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Receiving services at HIV clinics in Alabama
* Reported opioid and/or stimulant misuse
* 18 years of age or older

Exclusion Criteria:

* Receipt of SUD clinical care other than through HIV provider/clinic in the last 3 months
* Inability to engage in interviews independently without support (e.g., cognitive impairment)
* Currently psychotic
* Actively suicidal: presents with a suicide attempt or suicidal ideation
```

## Arms

- **Patients living with HIV and substance use** (EXPERIMENTAL) — Patients living with HIV and substance use, aged 18 and over. These participants are receiving services at HIV clinics in Alabama and must have reported opioid and/or stimulant misuse.

## Interventions

- **Telemedicine** (OTHER) — Routine care administered via telemedicine
- **Standard of care** (OTHER) — Standard of care, as received in HIV clinic settings

## Primary Outcomes

- **Percent of participants who have a follow-up healthcare visit** _(time frame: 1 month, 2 months, 3 months)_ — Follow up visit for care (either telemedicine or in person)

## Locations (1)

- University of Alabama at Birmingham, Birmingham, Alabama, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of alabama at birmingham|birmingham|alabama|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06370481.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06370481*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*